Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC

Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC

BackgroundNeoadjuvant therapy, which aims to achieve a pathological complete response (pCR) for better overall survival (OS) has several advantages for patients with early breast cancer (eBC) and subtypes of HER2-positive (HER2+) and triple-negative breast cancer (TNBC). However, there has been no l...

Full description

Bibliographic Details
Main Authors: Wei-Pang Chung, Chun-Ting Yang, Shuen-Ru Yang, Ching-Yen Su, Hsin-Wei Su, Shang-Yun Liu, Huang-Tz Ou
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
early breast cancer
HER2-positive breast cancer
triple-negative breast cancer
trastuzumab
platinum
neoadjuvant therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1022994/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1022994/full

Similar Items